Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Julio Chavez, MD
Videos
Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy
12/09/2025
Bilal Abid, MD, MS, FACP, MRCP, FRCP
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented...
12/09/2025
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Healthcare Resource Utilization for Patients With DLBCL and MM Comparable Between New and Established CAR T-Cell Therapy Centers
12/09/2025
Olalekan O. Oluwole
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell...
12/09/2025
Oncology
Jean-Marie Michot, MD
Conference Coverage
OLYMPIA-3 Trial: Odronextamab With CHOP Demonstrates Strong Efficacy and Manageable Safety for Patients With Newly Diagnosed DLBCL
12/07/2025
Jean-Marie Michot, MD
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP...
12/07/2025
Oncology
Giorgio Inghirami, MD
Videos
Patient-Derived Xenografts Demonstrate Promising Utility for Treating Patients With Lymphoma
10/15/2025
Giorgio Inghirami, MD
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Giorgio Inghirami, MD, shares insights into the use of patient derived xenografts for the treatment and management of various lymphomas.
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Giorgio Inghirami, MD, shares insights into the use of patient derived xenografts for the treatment and management of various lymphomas.
At the 2025 Lymphoma, Leukemia,...
10/15/2025
Oncology
Aine Hurley, MD
Conference Coverage
New Third Generation CAR-T Therapy Targets LBCL With Lower Toxicity Risk: ENABLE-2
06/26/2025
Aine Hurley, MD
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights into the ENABLE-2 clinical trial determining the safety and efficacy of WZTL-002 for patients with relapsed/refractory large B-cell lymphoma.
Aine Hurley, MD shares insights...
06/26/2025
Oncology
Krish Patel, MD
Conference Coverage
Dual-Target CAR T-Cell Therapy Demonstrates Promising Response Rates for R/R LBCL
06/23/2025
Krish Patel, MD
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish...
06/23/2025
Oncology

Recent Stories

Julio Chavez, MD
Videos
Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy
12/09/2025
Bilal Abid, MD, MS, FACP, MRCP, FRCP
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented...
12/09/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use